The Patented Medicine Prices Review Board (PMPRB) recently released draft guidelines operationalising the amended Patented Medicines Regulations for consultation (for further details please see "PMPRB releases draft guidelines operationalising amended Patented Medicines Regulations"). The consultation period ended on 14 February 2020, after two extensions.

Further, the PMPRB has released the presentations from its patentee webinar (17 January 2020), the industry forum (9 December 2019) and civil society forum (10 December 2019).

Notably, the patentee webinar:

  • highlights distinctions between the current and proposed guidelines;
  • provides two case studies of how the maximum rebated and maximum list prices will work in practice;
  • provides detail on the filing requirements under the new guidelines; and
  • provides further details on transition, including for grandfathered and gap medicines, and what to expect after 1 July 2020 when the guidelines come into force.

For further information on this topic please contact Abigail Smith at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smart-biggar.ca.


The Patented Medicine Prices Review Board (PMPRB) recently released draft guidelines operationalising the amended Patented Medicines Regulations for consultation (for further details please see "PMPRB releases draft guidelines operationalising amended Patented Medicines Regulations"). The consultation period ended on 14 February 2020, after two extensions.

Further, the PMPRB has released the presentations from its patentee webinar (17 January 2020), the industry forum (9 December 2019) and civil society forum (10 December 2019).

Notably, the patentee webinar:

  • highlights distinctions between the current and proposed guidelines;
  • provides two case studies of how the maximum rebated and maximum list prices will work in practice;
  • provides detail on the filing requirements under the new guidelines; and
  • provides further details on transition, including for grandfathered and gap medicines, and what to expect after 1 July 2020 when the guidelines come into force.

For further information on this topic please contact Abigail Smith at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smart-biggar.ca.